Combined gene therapy of endostatin and interleukin 12 with polyvinylpyrrolidone induces a potent antitumor effect on hepatoma

doi:10.3748/wjg.v10.i15.2195

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 15

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2912)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series.

Item

Count

PDF

316

HTML

2345

Figures (1-6)

251

Sum=2912

Aug 1, 2004 (publication date) through Nov 30, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Aug 1, 2004; 10(15): 2195-2200
Published online Aug 1, 2004. doi: 10.3748/wjg.v10.i15.2195

Full Size Figure Download Figure

Figure 4 Hepatoma angiogenesis inhibited by gene therapy of endostatin and IL-12. MVD (CD31staining, 200 × ) of hepatoma treated with pSecES/PVP (7.3 ± 1.2) (B), pmIL-12/PVP (10.0 ± 1.7) (C) or pSecES + pmIL-12/PVP (3.7 ± 1.2) (D) was less than that treated with pcDNA3.1/PVP (22.7 ± 3.1, P < 0.05) (A).

Citation: Li PY, Lin JS, Feng ZH, He YF, Zhou HJ, Ma X, Cai XK, Tian DA. Combined gene therapy of endostatin and interleukin 12 with polyvinylpyrrolidone induces a potent antitumor effect on hepatoma. World J Gastroenterol 2004; 10(15): 2195-2200
URL: https://www.wjgnet.com/1007-9327/full/v10/i15/2195.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i15.2195